Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cisplatin

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    994 result(s) found for: Cisplatin. Displaying page 1 of 50.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2020-003890-23 Sponsor Protocol Number: Cisplatin Start Date*: 2021-02-23
    Sponsor Name:Erasmus MC Cancer Institute
    Full Title: The nephroprotective effect of short hydration during cisplatin treatment in head and neck cancer patients.
    Medical condition: Cisplatin induced nephrotoxicity
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-002634-16 Sponsor Protocol Number: NL76533.041.21 Start Date*: 2021-08-25
    Sponsor Name:University Medical Center Utrecht
    Full Title: Low dose cisplatin weekly versus high dose cisplatin every three weeks in primary chemoradiation in sarcopenic patients with head and neck squamous cell carcinoma
    Medical condition: The IMP will be used to treat locally advanced head and neck squamous cell carcinoma (HNSCC). Patients with low skeletal muscle mass will be randomized between two schedules: 1) weekly 40 mg/m2 cis...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-002676-87 Sponsor Protocol Number: CA209-9TM Start Date*: 2018-02-23
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Nivolumab or Nivolumab plus Cisplatin, in Combination with Radiotherapy in Participants with Cisplatin Ineligible and Cisplatin Elig...
    Medical condition: Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GB (Completed) PL (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-001514-20 Sponsor Protocol Number: CA209-648 Start Date*: 2017-06-06
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Randomized Phase 3 Study of Nivolumab plus Ipilimumab or Nivolumab Combined with Fluorouracil plus Cisplatin versus Fluorouracil plus Cisplatin in Subjects with Unresectable Advanced, Recurrent o...
    Medical condition: Inoperable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10055476 Esophageal squamous cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA) PL (Completed) FR (Completed) DK (Completed) PT (Completed) IT (Prematurely Ended) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-003015-34 Sponsor Protocol Number: LDOS003 Start Date*: 2018-04-12
    Sponsor Name:Helix BioPharma Corp
    Full Title: A Phase II Open-Label, Randomized Study of Immunoconjugate L-DOS47 in Combination with Vinorelbine/Cisplatin Versus Vinorelbine/Cisplatin Alone in Patients with Lung Adenocarcinoma
    Medical condition: Lung adenocarcinoma chemotherapy naive or recurrent for which vinorelbine/cisplatin would be appropriate therapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025031 Lung adenocarcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Prematurely Ended) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-001341-42 Sponsor Protocol Number: 2005-001341-42 Start Date*: 2006-03-10
    Sponsor Name:Rigshospitalet
    Full Title: Treatment strategy in adrenocortical carcinomas Fase II trial with docetaxel and cisplatin in patients with locally advanced or disseminated adrenocortical carcinomas
    Medical condition: Fase II trial of taxotere and cisplatin in patients with advanced or metastatic adrenocortical carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-000663-18 Sponsor Protocol Number: UPT-fit-01 Start Date*: 2007-03-08
    Sponsor Name:Rigshospitalet, Onkologisk Klinik
    Full Title: Randomized fase II trial: comparing Cisplatin, Paclitaxel and Gemcitabine vs. Cisplatin, Paclitaxel, Gemcitabine and Avastin in patients with unknown primary tumors
    Medical condition: To test in a randomized fase II trial the effect of Cisplatin, Paclitaxel, Gemcitabine +/- Avastin in patients with unknown primary tumors between the age of 18 and 70 years old and with a perfoman...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-002026-39 Sponsor Protocol Number: N15LDC Start Date*: 2015-09-10
    Sponsor Name:NKI-AVL
    Full Title: The Effect of Prehydration on the Pharmacokinetics of Low-dose Cisplatin
    Medical condition: Tumor
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-001598-10 Sponsor Protocol Number: UCL/12/0158 Start Date*: 2012-12-21
    Sponsor Name:University College London
    Full Title: A phase I/II study of first line Ganetespib with pemetrexed/cisplatin, in patients with malignant pleural mesothelioma
    Medical condition: Malignant pleural mesothelioma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10035603 Pleural mesothelioma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-003881-14 Sponsor Protocol Number: CA209-901 Start Date*: 2017-06-12
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 3, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab, or with Standard of Care Chemotherapy, versus Standard of Care Chemotherapy in Participants with Previously Untreated ...
    Medical condition: Untreated Unresectable or Metastatic Urothelial Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10064467 Urothelial carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) NL (Trial now transitioned) ES (Ongoing) SE (Completed) FI (Completed) FR (Trial now transitioned) GR (Trial now transitioned) NO (Trial now transitioned) CZ (Trial now transitioned) DK (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-001879-37 Sponsor Protocol Number: ArtscanIII Start Date*: 2013-03-05
    Sponsor Name:Department of Oncology, Skåne University Hospital Lund
    Full Title: A randomized multicenter phase III study of cisplatin plus radiotherapy compared to cetuximab plus radiotherapy in locally advanced head and neck cancer
    Medical condition: Stage III and IV head and neck squamous cell cancer (HNSCC) without radiographic signs of distant metastases aimed for radiotherapy with curative intent
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071536 Head and neck cancer stage IV PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071537 Head and neck cancer stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-004692-31 Sponsor Protocol Number: CA017-078 Start Date*: 2019-03-18
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post- Surgery Therapy with Nivolumab...
    Medical condition: Bladder Cancer Muscle-Invasive Bladder Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10022877 Invasive bladder cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) AT (Trial now transitioned) FR (Trial now transitioned) BE (Trial now transitioned) NO (Trial now transitioned) NL (Trial now transitioned) FI (Trial now transitioned) GR (Trial now transitioned) ES (Ongoing) PT (Completed) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-001509-25 Sponsor Protocol Number: RHMCAN0860 Start Date*: 2012-09-25
    Sponsor Name:University Hospital Southampton NHS Foundation Trust
    Full Title: COAST - Cisplatin Ototoxicity attenuated by Aspirin Trial A randomised, Phase II, double-blind, placebo-controlled, two arm Trial to establish whether Aspirin can reduce hearing loss/ototoxicity fo...
    Medical condition: To establish whether Aspirin can reduce hearing loss/ototoxicity for patients receiving Cisplatin based chemotherapy.
    Disease: Version SOC Term Classification Code Term Level
    18.0 10013993 - Ear and labyrinth disorders 10033109 Ototoxicity PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-001356-37 Sponsor Protocol Number: NSGO-CC-0304 Start Date*: 2004-09-10
    Sponsor Name:Nordic Society for Gynecological Cancer
    Full Title: Phase I-II-III studies of Cisplatin and Combretastatin (CA4P) in recurrent or advanced servical cancer
    Medical condition: Metastatic or recurrent cervical cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-004031-37 Sponsor Protocol Number: 17.14 Start Date*: 2017-12-07
    Sponsor Name:Department of oncology, Odense University Hospital
    Full Title: A multicentre, single-arm, phase II study to investigate the safety and antiemetic efficacy of Akynzeo® (a fixed dose combination of palonosetron and netupitant) plus dexamethasone in patients rece...
    Medical condition: Eligible patients will have a diagnosis of cervical cancer, and be scheduled to receive fractionated radiotherapy and concomitant weekly cisplatin at a dose of ≥ 40 mg/m2 for at least five weeks. P...
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-000618-35 Sponsor Protocol Number: M07PGC Start Date*: 2007-11-29
    Sponsor Name:Rigshospitalet
    Full Title: PHASE II TRIAL OF PACLITAXEL, GEMCITABINE AND CISPLATIN IN PATIENTS WITH RELAPSING GERM CELL CANCER AFTER FIRST LINE CHEMOTHERAPY
    Medical condition: · The primary objective of this study is to investigate the combination of cisplatin/gemcitabine/paclitaxel, with respect to progression free survival in patients with germ cell tumours previously...
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: NL (Ongoing) DK (Completed) SK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-000358-21 Sponsor Protocol Number: D7919C00706 (ZD1839IL/0706) Start Date*: 2004-10-06
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase II Randomised, Double-blind, Placebo-controlled, Multicentre Comparative study of ZD1839 250 mg or 500 mg (Iressatm) given either continuously or concomitantly with cisplatin plus radiother...
    Medical condition: Untreated, unresected late stage III/IV non-metastatic head and neck squamous cell carcinoma
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2015-003953-16 Sponsor Protocol Number: OTO4008 Start Date*: 2016-04-05
    Sponsor Name:ÁREA DE ATENCIÓN INTEGRADA DE ALBACETE
    Full Title: A Phase IIIb study of the efficacy of dexamethasone in irreversible hearing loss prevention in subjects with Ototoxic Oncological Treatment. Otoprotection in cancer treatment.
    Medical condition: Cisplatin ototoxicity
    Disease: Version SOC Term Classification Code Term Level
    18.1 10013993 - Ear and labyrinth disorders 10033109 Ototoxicity PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-005095-28 Sponsor Protocol Number: IRST186.02 Start Date*: 2015-04-16
    Sponsor Name:ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS
    Full Title: Olaparib as salvage treatment for cisplatin-resistant germ cell tumor.
    Medical condition: cisplatin-resistant germ cell tumor
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061184 Germ cell cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-004030-40 Sponsor Protocol Number: TOGA 0502 Start Date*: 2006-02-06
    Sponsor Name:Thoracale Oncologie Groep Antwerpen
    Full Title: A RANDOMIZED MULTICENTER PHASE II STUY OF INDUCTION THERAPY WITH PEMETREXED AND CISPLATIN FOLLOWED BY CHEMORADIATION WITH PEMETREXED VERSUS CHEMORADIATION WITH PEMETREXED FOLLOWED BY CONSOLIDATION ...
    Medical condition: Non-Small Cell Lung Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 18 20:42:54 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA